Literature DB >> 18926161

Long-term mortality with multiple treadmill exercise test abnormalities: comparison between patients with and without cardiovascular disease.

Bilal Aijaz1, Luciano Babuin, Ray W Squires, Stephen L Kopecky, Bruce D Johnson, Randal J Thomas, Thomas G Allison.   

Abstract

BACKGROUND: Poor exercise capacity, abnormal heart rate responses, and electrocardiographic abnormalities during treadmill exercise testing independently predict mortality. The combined relationship of these 3 variables to determine the incremental increase in mortality was compared in groups with and without known cardiovascular disease (CVD).
METHODS: Patients referred for treadmill exercise testing during 1986 to 1991 were included. Exercise capacity <74% (of age- and gender-predicted value), heart rate reserve of <68 beat/min, and horizontal or down-sloping ST depression of > or =1 mm were considered abnormal. Cox proportional hazards regression was used to determine all-cause mortality (average follow-up of 16 years) based on the number of exercise test abnormalities (0, 1, 2, or all 3).
RESULTS: Among 10,897 patients, 20.9% (n = 2,277) had CVD. Poor exercise capacity and limited heart rate reserve were associated with increased risk of mortality (P < .0001) in both groups; however, abnormal exercise electrocardiogram was associated with an increased risk of mortality in the no-CVD group only (P < .0001). A graded increase in mortality was observed with increase in number of abnormal exercise test results in both groups. Patients without CVD having 2 or 3 abnormal exercise test results had a similar age-adjusted risk of long-term mortality as those with CVD but normal exercise test results, with a hazard ratio comparing these groups = 1.01 (95% CI 0.79-1.28).
CONCLUSIONS: The combinatorial approach validates the prognostic significance of multiple exercise test variables. The presence of > or =2 exercise test abnormalities may constitute a "CVD risk equivalent" in patients without CVD.

Entities:  

Mesh:

Year:  2008        PMID: 18926161     DOI: 10.1016/j.ahj.2008.05.026

Source DB:  PubMed          Journal:  Am Heart J        ISSN: 0002-8703            Impact factor:   4.749


  6 in total

1.  Inherent aerobic capacity-dependent differences in breast carcinogenesis.

Authors:  Henry J Thompson; Lee W Jones; Lauren G Koch; Steven L Britton; Elizabeth S Neil; John N McGinley
Journal:  Carcinogenesis       Date:  2017-09-01       Impact factor: 4.944

2.  Maximal exercise electrocardiographic responses and coronary heart disease mortality among men with metabolic syndrome.

Authors:  G William Lyerly; Xuemei Sui; Timothy S Church; Carl J Lavie; Gregory A Hand; Steven N Blair
Journal:  Mayo Clin Proc       Date:  2010-02-16       Impact factor: 7.616

Review 3.  Exercise training and cardiac rehabilitation in primary and secondary prevention of coronary heart disease.

Authors:  Carl J Lavie; Randal J Thomas; Ray W Squires; Thomas G Allison; Richard V Milani
Journal:  Mayo Clin Proc       Date:  2009-04       Impact factor: 7.616

4.  False-positive stress testing: Does endothelial vascular dysfunction contribute to ST-segment depression in women? A pilot study.

Authors:  Shilpa Sharma; Puja K Mehta; Reza Arsanjani; Tara Sedlak; Zachary Hobel; Chrisandra Shufelt; Erika Jones; Paul Kligfield; David Mortara; Michael Laks; Márcio Diniz; C Noel Bairey Merz
Journal:  Clin Cardiol       Date:  2018-08-17       Impact factor: 3.287

5.  Fitness level and body composition indices: cross-sectional study among Malaysian adolescent.

Authors:  Redzal Abu Hanifah; Hazreen Abdul Majid; Muhammad Yazid Jalaludin; Nabilla Al-Sadat; Liam J Murray; Marie Cantwell; Tin Tin Su; Azmi Mohamed Nahar
Journal:  BMC Public Health       Date:  2014-11-24       Impact factor: 3.295

6.  Cardiopulmonary fitness and heart rate recovery as predictors of mortality in a referral population.

Authors:  Abhijeet Dhoble; Brian D Lahr; Thomas G Allison; Stephen L Kopecky
Journal:  J Am Heart Assoc       Date:  2014-03-24       Impact factor: 5.501

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.